A phase 1 trial has reported positive safety findings of SON-1010 among patients with advanced leiomyosarcoma (LMS) or ...

Call it a new type of precision medicine. A Northeastern researcher says one day oncologists may be able to write ...

New research suggests that a larger waist circumference is a bigger risk factor than body mass index (BMI) for ...

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

PARP7 is a mono-ADP-ribosyl transferase (mono-ART) which has recently gained attention due to its emerging role as a negative ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer. Initiation of trial sites underway for ground ...

Peanuts are a favorite snack for many people. They’re crunchy, tasty, and often praised for being healthy. But if you or someone you know is dealing with cancer, a new study suggests it might be time ...

Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

Rodabe Amaria, MD, discusses the current role of OBX-115 for the treatment of patients with checkpoint inhibitor-resistant metastatic melanoma.

Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, ...

Dying from colon cancer in the end stage means that treatments are no longer working or need to be stopped due to side effects. The cancer has spread throughout the body, and the condition is ...

Results showed the agent lessened severity of cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome (ICANS) for a majority of treated patients. “We expected to see ...